PMID: 2507323Jan 1, 1989Paper

Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia

European Journal of Clinical Pharmacology
R StohlerW F Riesen

Abstract

Sixteen patients with primary hypercholesterolaemia received double-blind either fenofibrate (n = 8; 200 mg bid) or the HMG-CoA reductase inhibitor simvastatin (n = 8; 20 mg q.p.m. [corrected] or 40 mg q.p.m. [corrected] if LDL-cholesterol did not fall below 3.6 mmol.l-1 after 4 weeks of treatment). Simvastatin reduced total cholesterol from 9.7 to 7.0 mmol.l-1 after 10 weeks (-28%), and fenofibrate reduced it from 9.2 to 7.7 mmol.l-1 (-15%). The decrease was less during fenofibrate than during simvastatin treatment (time x drug: p = 0.02). Serum LDL-cholesterol fell from 8.3 to 5.3 mmol.l-1 (-36%) during simvastatin and from 7.2 to 6.0 mmol.l-1 (-16%) during fenofibrate administration. Again, the effect of simvastatin was more pronounced than that of fenofibrate (time x drug: p = 0.03). HDL-cholesterol increased significantly from 1.1 to 1.2 mmol.l-1 (+13%) during fenofibrate administration and it did not change significantly during simvastatin. Serum triglycerides fell from 1.3 to 1.1 mmol.l-1 (-16%) during simvastatin, and even more significantly from 2.2 to 1.1 mmol.l-1 (-51%) during fenofibrate (time x drug: p = 0.002). Apolipoprotein B fell on simvastatin from 1.9 to 1.4 g.l-1 (-24%) and from 1.8 to 1.4 g.l-1 (-22%) durin...Continue Reading

References

Jan 1, 1988·European Journal of Clinical Pharmacology·S BertoliniA Carozzi
Jul 7, 1988·The New England Journal of Medicine·S M Grundy
Jun 19, 1987·JAMA : the Journal of the American Medical Association·D H BlankenhornL Cashin-Hemphill
Jan 14, 1988·The New England Journal of Medicine·A Garg, S M Grundy
Nov 1, 1986·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·W V BrownP Samuel
Apr 24, 1987·JAMA : the Journal of the American Medical Association·K M AndersonD Levy
Oct 15, 1985·Clinica Chimica Acta; International Journal of Clinical Chemistry·P W WilsonH B Brewer
Mar 1, 1985·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J ShepherdC J Packard
Jan 1, 1971·Annals of Internal Medicine·W B KannelP M McNamara

❮ Previous
Next ❯

Citations

Aug 29, 2007·International Journal of Nanomedicine·Konstantinos Tziomalos, Vasilios G Athyros
Oct 26, 1999·The Annals of Pharmacotherapy·D R Guay
Mar 1, 1991·DICP : the Annals of Pharmacotherapy·V F Mauro, J L MacDonald

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.